Printer Friendly

CEO INTERVIEW: WILLIAM KOSTER - NEUROGEN CORPORATION (NRGN).

(SAM235) WILLIAM KOSTER - NEUROGEN CORPORATION (NRGN). Describes the company's business and its background; prospects for the industry, with positive and negative trends; competitive threats; strategic opportunities for the firm including its marketing plans and acquisition potential; management strength and organization; and the financial prospects of the firm looking forward. Sector: Biotechnology. Published date 6/2/04. Tickers featured: NRGN. Complete text approximately 3000 words. Document # SAM235.

CEO INTERVIEWS, The Wall Street Transcript, 67 Wall Street, NY 10005. Voice (212) 952 7433. Fax: (212) 668-9842. E-mail: information@twst.com.

***
COPYRIGHT 2004 Wall Street Transcript Corporation
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Wall Street Transcript Digest
Geographic Code:1USA
Date:Jun 2, 2004
Words:88
Previous Article:CEO INTERVIEW: JEFFERY STOOPS - SBA COMMUNICATIONS CORPORATION (SBAC).
Next Article:CEO INTERVIEW: JOEL KIMBROUGH - ACCREDO HEALTH INC (ACDO).
Topics:


Related Articles
Neurogen announces new licensing agreement with Pfizer's Animal Health division
HARRY PENNER JR. - NEUROGEN CORPORATION (NRGN).
STEPHEN DAVIS - NEUROGEN CORPORATION (NRGN).
CEO INTERVIEW: STEPHEN DAVIS - NEUROGEN CORPORATION (NRGN).
Neurogen and Aventis PHARMA announce worldwide collaboration.
CEO INTERVIEW: WILLIAM KOSTER - NEUROGEN CORPORATION (NRGN).
Neurogen, Merck agreement for pain drugs cleared.
New genes' discovery confirms immune system may play a role in schizophrenia.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters